Claritev and Burjeel Holdings partner on healthcare tech

MCLEAN, Va. & ABU DHABI, United Arab Emirates - Claritev Corporation (NYSE: CTEV) and Claims Care Revenue Cycle Management LLC, a division of Burjeel Holdings (ADX: BURJEEL), have solidified their strategic partnership to enhance revenue cycle management (RCM) in the Middle East and North Africa (MENA) region. This collaboration, following a memorandum of understanding signed last month, combines Claritev’s advanced claims analytics and AI-driven solutions with Claims Care’s regional expertise.

The alliance is set to drive innovation in healthcare RCM, aiming to improve transparency, affordability, and quality of care while reducing costs. The partnership will focus on developing new RCM solutions that integrate Claritev’s technology with Claims Care’s operational capabilities, with Claritev expecting to begin generating regional revenues within 2025.

Key aspects of the partnership include accelerated product development tailored for the MENA market, operational synergies through business process transitions, and enhanced healthcare delivery by combining both companies’ strengths. The strategic market expansion marks the beginning of a long-term effort to extend Claritev’s offerings in the MENA region.

John Sunil, Group CEO of Burjeel Holdings, emphasized the significance of collaboration in driving healthcare innovation, stating that this milestone enables them to deliver unparalleled solutions in healthcare services. Travis Dalton, Chairman, CEO, and President of Claritev, echoed this sentiment, expressing excitement over the partnership’s potential to improve healthcare standards and introduce new solutions to the market.

Claritev, formerly known as MultiPlan, is a healthcare technology company providing solutions to improve affordability and quality in the U.S. healthcare system. Claims Care, established in 2016, is a significant independent RCM provider in the MENA region, operating under Burjeel Holdings and managing over 3.5 million records and 5.4 million claims.

The press release also contains forward-looking statements regarding Claritev’s strategy and business prospects in the MENA region and anticipated revenue for 2025. However, these statements are subject to various risks, uncertainties, and assumptions, and actual results may differ materially from those projected.

This news article is based on a press release statement. For comprehensive analysis and additional insights about Claritev’s financial health, including 10+ exclusive ProTips and detailed metrics, visit InvestingPro, where you can access the complete Pro Research Report, transforming complex Wall Street data into actionable intelligence.

In other recent news, Claritev Corp reported a slight decline in its Q1 2025 revenue, which fell 1.4% year-over-year to $231.3 million. Despite this dip, the company remains optimistic, reaffirming its full-year revenue guidance and anticipating a return to growth by the third quarter. Claritev’s Payment and Revenue Integrity segment showed a strong performance, with a notable 9.7% increase in revenue year-over-year. The company is also focusing on strategic initiatives such as international expansion and new product enhancements. Analysts from Nephron Research and JPMorgan have shown interest in Claritev’s strategic partnerships and new revenue models, particularly the collaboration with Lantern. This partnership aims to enhance healthcare outcomes by navigating patients to high-quality, cost-effective providers. Claritev’s ongoing transformation efforts include a digital shift to Oracle Cloud Infrastructure, which is expected to improve operational efficiency. The company is also exploring opportunities in international markets, particularly in the Middle East, in collaboration with Burjeel Holdings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.